注册 | 登录
所有产品
  • 所有产品
  • 一抗
  • 裂解液
>   首页   >   产品   >   一抗   >   精选抗体   >   磷酸化抗体   >   Phospho-EGFR(Y1125) Antibody   

Phospho-EGFR(Y1125) Antibody

Peptide Affinity Purified Rabbit Polyclonal Antibody (Pab)

     
  • 6 - Phospho-EGFR(Y1125) Antibody AP3376a
    Dot blot analysis of Phospho-EGFR-Y1125 Antibody (Cat. #AP3376a) and EGFR Non Phospho-specific Pab on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.
  • 产品详情
  • 文献引用 : 2
  • 实验流程
  • 背景知识
Product info
Application
  • Applications Legend:
  • E=ELISA
  • WB=Western Blotting
  • IHC=Immunohistochemistry
  • IHC-P=Immunohistochemistry (Paraffin)
  • IP=Immunoprecipitation
  • IF=Immunofluorescence
  • IC=Immunochemistry
  • ICC=Immunocytochemistry
  • FC=Flow Cytometry
  • DB=Dot Blot
DB, E
Primary Accession P00533
Reactivity Human
Host Rabbit
Clonality Polyclonal
Isotype Rabbit Ig
Calculated MW 134277 Da
Additional info
Gene ID 1956
Other Names Epidermal growth factor receptor, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, EGFR, ERBB, ERBB1, HER1
Target/Specificity This EGFR Antibody is generated from rabbits immunized with a KLH conjugated synthetic phosphopeptide corresponding to amino acid residues surrounding Y1125 of human EGFR.
Dilution DB~~1:500
Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is first purified by protein A affinity chromatography. Then, the antibody fraction is peptide affinity purified in a 2-step procedure with peptides. The antibody is eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.
StorageMaintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
PrecautionsPhospho-EGFR(Y1125) Antibody is for research use only and not for use in diagnostic or therapeutic procedures.
Protein Information
Name EGFR
Synonyms ERBB, ERBB1, HER1
Function Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses (PubMed:2790960, PubMed:10805725, PubMed:27153536). Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF (PubMed:2790960, PubMed:7679104, PubMed:8144591, PubMed:9419975, PubMed:15611079, PubMed:12297049, PubMed:27153536, PubMed:20837704). Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS- RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules (PubMed:27153536). May also activate the NF-kappa-B signaling cascade (PubMed:11116146). Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling (PubMed:11602604). Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin (PubMed:11483589). Plays a role in enhancing learning and memory performance (By similarity).
Cellular Location Cell membrane; Single- pass type I membrane protein Endoplasmic reticulum membrane; Single-pass type I membrane protein. Golgi apparatus membrane; Single-pass type I membrane protein. Nucleus membrane; Single-pass type I membrane protein. Endosome. Endosome membrane. Nucleus. Note=In response to EGF, translocated from the cell membrane to the nucleus via Golgi and ER (PubMed:20674546). Endocytosed upon activation by ligand (PubMed:2790960, PubMed:17182860, PubMed:27153536). Colocalized with GPER1 in the nucleus of estrogen agonist-induced cancer- associated fibroblasts (CAF) (PubMed:20551055)
Tissue Location Ubiquitously expressed. Isoform 2 is also expressed in ovarian cancers.
Research Areas
Nanoformulated paclitaxel and AZD9291 synergistically eradicate non-small-cell lung cancers in vivo.
Author : Wang XS1,Zhang L1,Li X2,Kong DJ1,Hu XC1,Ding XZ1,Yang JQ1,Zhao MQ1,He Y2,Lam KS2,Gao SG1,Lin TY3,Li Y2.
Nanomedicine (Lond). 2018 Jun 6. doi: 10.2217/nnm-2017-0355. [Epub ahead of print]
29874151
Identification of mutant K-Ras-dependent phenotypes using a panel of isogenic cell lines.
Author : Vartanian S1, Bentley C, Brauer MJ, Li L, Shirasawa S, Sasazuki T, Kim JS, Haverty P, Stawiski E, Modrusan Z, Waldman T, Stokoe D.
J Biol Chem. 2013 Jan 25;288(4):2403-13. doi: 10.1074/jbc.M112.394130. Epub 2012 Nov 27.
23188824

BACKGROUND

EGFR is a transmembrane glycoprotein that is a member of a family of protein tyrosine kinases crucial in maintaining a normal balance in cell growth and development. A prototype member of the type 1 receptor tyrosine kinases, EGFR is encoded by the cellular oncogene cerbB1. EGFR has an extracellular ligand binding domain, a single transmembrane region, and cytoplasmic domain which is composed of a tyrosine kinase domain and a carboxy terminal domain. The carboxy terminal domain contains at least four tyrosine autophosphorylation sites. Increased production or activation of EGFR has been associated with poor prognosis in a variety of tumors. EGFR overexpression is observed in tumors of the head and neck, brain, bladder, stomach, breast, lung, endometrium, cervix, vulva, ovary, esophagus, stomach and in squamous cell carcinoma.

REFERENCES

Aifa, S., et al., Exp. Cell Res. 302(1):108-114 (2005). Adams, T.E., et al., Growth Factors 22(2):89-95 (2004). Ichinose, J., et al., Biochem. Biophys. Res. Commun. 324(3):1143-1149 (2004). Kuribayashi, A., et al., Endocrinology 145(11):4976-4984 (2004). Kapoor, G.S., et al., Mol. Cell. Biol. 24(2):823-836 (2004).

FeedBack

终于等到您。感谢您使用ABGENT(百奇生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。

如有疑问,联系:0512-69552906 tech.abgent@wuxiapptec.com.


我要评价